MBX Biosciences initiated with a Buy at Stifel

Stifel initiated coverage of MBX Biosciences with a Buy rating and $40 price target The firm cites the company’s “robust and productive” technology platform of precision endocrin peptides for rare endocrine and metabolic disorders that represent multi-billion dollar opportunities for the Buy rating. MBX has engineered pharmaceutical properties for optimal therapeutic use-preserving peptide integrity, reducing variability, increasing duration of action, and importantly reducing injection frequency, the analyst tells investors in a research note.